Cytochrome P450 2C19 polymorphism and clopidogrel after MI - Authors' reply

The Lancet

Volumn 373, Issue 9670, 2009, Pages 1172-1173

  Collet, JP ^a   Hulot, JS ^b   Montalescot, G ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

CLINICAL TRIAL; DNA POLYMORPHISM; DRUG WITHDRAWAL; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; LETTER; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; GENETIC POLYMORPHISM; GENETICS; LIVER; METABOLISM; NOTE; SAFETY; TREATMENT OUTCOME;

ARYL HYDROCARBON HYDROXYLASES; HUMANS; LIVER; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; SAFETY; TICLOPIDINE; TREATMENT OUTCOME;

EID: 63349111759     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60682-6     Document Type: Letter

References (2)

1. Trenk D., Hochholzer W., Fromm M.F., et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51 (2008) 1925-1934
2. Bonello L., Camoin-Jau L., Arques S., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized, prospective study. J Am Coll Cardiol 51 (2008) 1404-1411